ImmunoGen, Inc. (IMGN)
-NasdaqGS | Prev Close: | 16.38 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 17.25 x 100 |
|---|
| 1y Target Est: | 15.10 |
|---|
| Beta: | 2 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 10.85 - 18.83 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 704,244 |
|---|
| Market Cap: | 1.38B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.89 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why ImmunoGen Is a Buy Right Now?at Motley Fool(Sat, Jun 15)
- A Trio of Cancer Immunotherapy Innovatorsat Motley Fool(Sat, Jun 15)
- ImmunoGen's Management Presents at Goldman Sachs 34th Annual Global Healthcare Conference (Transcript)at Seeking Alpha(Thu, Jun 13)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, Jun 9)
- IMMUNOGEN INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, Jun 7)
- First Clinical Data Presented with IMGN853, ImmunoGen, Inc.’s Potential New Therapy for Ovarian and Other CancersBusiness Wire(Mon, Jun 3)
- Tackling Cancer: Your Best Investing Ideasat Motley Fool(Sun, Jun 2)
- Why Immunomedics Shares Soaredat Motley Fool(Thu, May 30)
- ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor ConferencesBusiness Wire(Thu, May 30)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Companies Invest in Antibodies That Fight Tumorsat Motley Fool(Mon, May 13)
- ImmunoGen's Management Presents at Credit Suisse Antibody Day Conference (Transcript)at Seeking Alpha(Sat, May 11)
- IMMUNOGEN INC FinancialsEDGAR Online Financials(Fri, May 10)
- ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Priceat Seeking Alpha(Thu, May 9)
- IMMUNOGEN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 39.95 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.93 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.30 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology.
View More